Sells glaucoma devices and medicines and corneal therapies to eye-care providers, while developing treatments for retinal disease.
10-K for FY2025, filed Feb 23, 2026Glaukos is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing…View ↗
Glaucoma is a group of eye diseases characterized by progressive, irreversible and largely asymptomatic vision loss in which elevated…View ↗
In December 2023, we received FDA approval for iDose TR, indicated for the reduction of IOP in patients with open-angle glaucoma or ocular…View ↗
The cornea, the eye’s outermost layer, is a clear, dome-shaped surface that functions best as a lens when the cornea is strong and shaped…View ↗
Our pharmaceutical iLink platform uses a suite of novel single-use drug formulations that are bio-activated by our proprietary systems to…View ↗
Our global sales efforts and promotional activities are currently aimed at ophthalmic surgeons and other eye care professionals. Our…View ↗
Customers buy eye-care products; the company charges for products delivered, then collects under invoice terms.
10-K for FY2025, filed Feb 23, 2026
10-K for FY2025, filed Feb 23, 2026
FY2025 revenue by product or service ↗$507.4M
10-K for FY2025, filed Feb 23, 2026
$507.4M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Glaucoma
Sold outright
10-K for FY2025, filed Feb 23, 2026 |
83%
FY2022: 76%
|
Glaucoma, FY2025
$421.1M Sources
|
Sold outright |
|
Corneal Health
Sold outright
10-K for FY2025, filed Feb 23, 2026 |
17%
FY2022: 24%
|
Corneal Health, FY2025
$86.4M Sources
|
Sold outright |
Ophthalmic surgeons and other eye-care professionals are the sales audience; ambulatory surgery centers, hospitals and private practices are primary customers. U.S. sales are mainly direct, while international sales run mostly through direct subsidiaries, with independent distributors in some countries.
10-K for FY2025, filed Feb 23, 2026Our global sales efforts and promotional activities are currently aimed at ophthalmic surgeons and other eye care professionals. Our…View ↗
No. It lost $187.7M in FY2025.
10-Q for Q3 FY2026, filed Oct 28, 2026
$2MView ↗
10-Q for Q3 FY2026, filed Oct 28, 2026
Open tableView ↗
8-K, filed Jul 29, 2026
Glaukos now expects full-year 2026 global consolidated net sales of $680 - $700 million, up from its previous guidance of $620 - $635…View ↗
Growing. Revenue grew 73% in 4 years, from $294M in FY2021 to $507.4M in FY2025, about 15% a year.
iDose becomes a commercial product
The glaucoma portfolio has moved from an investigational implant to a marketed procedural drug: iDose TR is now commercialized alongside the stent products.
10-K for FY2022, filed Feb 24, 2023 10-K for FY2025, filed Feb 23, 2026We are also developing several pipeline products for the treatment of glaucoma patients, including iDose TR, which has not yet been…View ↗
Epioxa advances to approval
The corneal business has moved beyond epi-off therapy and clinical work on epi-on: Epioxa is approved and launch preparation is underway.
10-K for FY2022, filed Feb 24, 2023 10-K for FY2025, filed Feb 23, 2026Our pharmaceutical iLink platform uses a suite of novel single-use drug formulations that are bio-activated by our proprietary systems to…View ↗
Our KXL System, which delivers UVA light to a large portion of the cornea, in conjunction with our Photrexa therapy, was approved by the…View ↗
Competes with Alcon, Sight Sciences, AbbVie, Iantrek, New World Medical, Epion Therapeutics, PeschkeTrade, Johnson & Johnson, Novartis, Genentech/Roche, Regeneron Pharmaceuticals, and Bayer
10-K for FY2025, filed Feb 23, 2026In glaucoma, our MIGS offerings primarily compete against Alcon, Sight Sciences, AbbVie, Iantrek, and New World Medical. Our procedural…View ↗
Loading...